Disclosed are dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives of Formula (A) or (B), crystal structures and pharmaceutical compositions thereof, and methods for their preparation. Specific examples of the compounds of Formula A and B include: (1S,2S,3S,4R,5S)-1-hydroxymethyl-5-[3-(4-methoxy-benzyl)-4-methyl-phenyl]-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol, 2-(4-ethoxybenzyl)-4-((1S,2S,3S,4R,5S)-2,3,4-trihydroxy-1-(hydroxymethyl)-6,8-dioxa-bicyclo[3,2,1]oct-5-yl)benzonitrile, and (1S,2S,3S,4R,5S)-5-{ 4-chloro-3-[4-(oxetan-3-yloxy)-benzyl]-phenyl} -1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol. Compounds of Formula (A) and (B) are sodium-glucose co-transporter (SGLT) inhibitors and are useful for treating obesity and obesity-related disorders, Type 2 diabetes and diabetes related disorders.
